Increased anticoagulant activity of warfarin used in combination with doxifluridine

Cancer Chemotherapy and Pharmacology

Volumn 66, Issue 5, 2010, Pages 969-972

  Nakajima, Masaru ^a   Genda, Tomoo ^a   Suehira, Mayu ^b   Satoh, Hiroki ^b   Miki, Akiko ^b   Hori, Satoko ^b   Sawada, Yasufumi ^b  

^a Iida Municipal Hospital   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Capecitabine; Doxifluridine (5 DFUR); Fluoropyrimidine Antitumor Agent; INR; Warfarin

Indexed keywords

CAPECITABINE; DOXIFLURIDINE; WARFARIN;

AGED; ANTICOAGULATION; ARTICLE; BLURRED VISION; BREAST CANCER; CASE REPORT; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG POTENTIATION; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAINTENANCE DRUG DOSE; MASTECTOMY; MITRAL VALVE REGURGITATION; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RECURRENT CANCER;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLOXURIDINE; FLUOROURACIL; HUMANS; INTERNATIONAL NORMALIZED RATIO; WARFARIN;

EID: 77956231596     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1249-5     Document Type: Article

References (17)

1. JM Kolesar CL Johnson BL Freeberg JD Berlin JH Schiller 1999 Warfarin-5-FU interaction-a consecutive case series Pharmacotherapy 19 12 1445 1449 10.1592/phco.19.18.1445.30897 1:CAS:528:DC%2BD3cXivF2rug%3D%3D 10600095
2. MW Saif 2005 An adverse interaction between warfarin and fluoropyrimidines revisited Clin Colorectal Cancer 5 3 175 180 10.3816/CCC.2005.n.028 16197620
3. HR Shah L Ledbetter R Diasio MW Saif 2006 A retrospective study of coagulation abnormalities in patients receiving concomitant capecitabine and warfarin Clin Colorectal Cancer 5 5 354 358 10.3816/CCC.2006.n.006 1:CAS:528:DC%2BD28Xit1Grt7w%3D 16512995
4. K Isaacs N Haim 2005 Adverse interaction between capecitabine and warfarin resulting in altered coagulation parameters and bleeding: case report and review of the literature J Chemother 17 3 339 342 1:STN:280: DC%2BD2MzotFSitA%3D%3D 16038530
5. R Camidge B Reigner J Cassidy S Grange M Abt E Weidekamm D Jodrell 2005 Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancer J Clin Oncol 23 21 4719 4725 10.1200/JCO.2005.09.129 1:CAS:528:DC%2BD2MXotFars70%3D 16034047
6. Y Yildirim O Ozyilkan Z Akcali B Basturk 2006 Drug interaction between capecitabine and warfarin: a case report and review of the literature Int J Clin Pharmacol Ther 44 2 80 82 1:STN:280:DC%2BD287hsF2itg%3D%3D 16502767
7. LM Janney NV Waterbury 2005 Capecitabine-warfarin interaction Ann Pharmacother 39 9 1546 1551 10.1345/aph.1G153 16014372
8. Y Yasui T Nishiguchi A Yamamoto C Fujii M Fujino M Tsuge M Ohno J Azuma T Matsumura H Ohsato S Anami H Furukawa 2008 A case of bleeding tendency due to warfarin in a patient treated with chemotherapy by S-1 Gan To Kagaku Ryoho 35 8 1367 1370 18701850 (in Japanese)
9. H Ebi Y Sigeoka T Saeki K Kawada T Igarashi N Usubuchi R Ueda Y Sasaki H Minami 2005 Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5′-deoxy-5-fluorouridine (5′-DFUR) Cancer Chemother Pharmacol 56 2 205 211 10.1007/s00280-004-0934-7 1:CAS:528:DC%2BD2MXksl2gsr0%3D 15844007
10. DR Budman 2000 Capecitabine Invest New Drugs 18 4 355 363 10.1023/A:1006449315650 1:CAS:528:DC%2BD3cXotFCqu70%3D 11081571
11. CM Walko C Lindley 2005 Capecitabine: a review Clin Ther 27 1 23 44 10.1016/j.clinthera.2005.01.005 1:CAS:528:DC%2BD2MXis1WltLg%3D 15763604
12. A Gunes U Coskun C Boruban N Gunel MO Babaoglu O Sencan A Bozkurt A Rane M Hassan H Zengil U Yasar 2006 Inhibitory effect of 5-fluorouracil on cytochrome P450 2C9 activity in cancer patients Basic Clin Pharmacol Toxicol 98 2 197 200 10.1111/j.1742-7843.2006.pto-304.x 1:CAS:528:DC%2BD28XhvFOrur4%3D 16445595
13. M Naganuma T Shiga K Nishikata T Tsuchiya H Kasanuki E Fujii 2001 Role of desethylamiodarone in the anticoagulation effect of concurrent amiodarone and warfarin therapy J Cardiovasc Pharmacol Ther 6 363 367 10.1177/ 107424840100600405 1:CAS:528:DC%2BD38XitVCrsbs%3D 11907638
14. A Tsuda J Fujiyama A Miki S Hori H Ohtani Y Sawada 2008 The first case of phenytoin intoxication associated with the concomitant use of phenytoin and TS-1, a combination preparation of tegafur, gimeracil, and oteracil potassium Cancer Chemother Pharmacol 62 3 427 432 10.1007/s00280-007-0621-6 1:CAS:528:DC%2BD1cXnt1Cjs7w%3D 18026730
15. LS Kaminsky ZY Zhang 1997 Human P450 metabolism of warfarin Pharmacol Ther 73 1 67 74 10.1016/S0163-7258(96)00140-4 1:CAS:528:DyaK28Xns1Cjsrw%3D 9014207
16. Xeloda® label approved on 06/15/2005, Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2005/020896s016lbl.pdf
17. HM Pinedo GF Peters 1988 Fluorouracil: biochemistry and pharmacology J Clin Oncol 6 10 1653 1664 1:CAS:528:DyaL1MXotA%3D%3D 3049954